High-Fidelity Nuclease For Therapeutic Breakthroughs

The hfCas12Max nuclease, developed by Synthego in partnership with Huidagene Therapeutics, is a high-fidelity tool for CRISPR-based therapies. Designed to address limitations of other nucleases, hfCas12Max features broad PAM sequence recognition, allowing greater flexibility in gene editing. Its compact size ensures easy integration into diverse delivery systems, while its high editing efficiency and minimal off-target effects make it ideal for therapeutic applications.

Performance assessments show that hfCas12Max achieves an average editing efficiency of 60% across various cell types, including T cells and HEK293T cells. This high efficiency supports both single and double gene knockouts, demonstrated through targeted edits of the TRAC and B2M genes. Sanger sequencing and flow cytometry confirm precise gene modifications with minimal disruption to cell viability.

Compared to other Cas12 variants, hfCas12Max exhibits significantly fewer off-target effects, as verified through next-generation sequencing (NGS) at critical genomic loci. This reliability reduces safety concerns, making hfCas12Max suitable for clinical development.

Synthego’s mission is to advance life sciences by providing comprehensive CRISPR solutions from research to clinical trials. With automation, machine learning, and regulatory support, Synthego ensures high-quality reagents and efficient workflows. Legal use of hfCas12Max is tied to proprietary guide RNAs from Synthego, ensuring optimized performance for customers.

This brochure explores the superior precision and efficiency of hfCas12Max and why it would make an ideal choice for researchers developing CRISPR-based therapeutics, promising breakthroughs in genome engineering with minimized risks.